{"id":555271,"date":"2026-06-16T21:44:54","date_gmt":"2026-06-16T19:44:54","guid":{"rendered":"https:\/\/medizinonline.com\/evaluations-de-levolution-a-laide-de-donnees-actuelles-a-long-terme-et-de-donnees-du-monde-reel\/"},"modified":"2026-04-23T16:28:43","modified_gmt":"2026-04-23T14:28:43","slug":"evaluations-de-levolution-a-laide-de-donnees-actuelles-a-long-terme-et-de-donnees-du-monde-reel","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/evaluations-de-levolution-a-laide-de-donnees-actuelles-a-long-terme-et-de-donnees-du-monde-reel\/","title":{"rendered":"\u00c9valuations de l’\u00e9volution \u00e0 l’aide de donn\u00e9es actuelles \u00e0 long terme et de donn\u00e9es du monde r\u00e9el"},"content":{"rendered":"\n

Un large \u00e9ventail d’agents syst\u00e9miques est d\u00e9sormais disponible pour le traitement du psoriasis mod\u00e9r\u00e9 \u00e0 s\u00e9v\u00e8re. Lors du congr\u00e8s de la DDG de cette ann\u00e9e “Dermatologie compacte + pratique”, diff\u00e9rentes \u00e9tudes ont \u00e9t\u00e9 pr\u00e9sent\u00e9es, entre autres sur les produits biologiques ixekizumab, bimekizumab et risankizumab, ainsi que sur l’inhibiteur de tyrosine kinase 2 (TYK2) deucravacitinib, dans lesquelles l’accent \u00e9tait mis sur l’\u00e9valuation des effets th\u00e9rapeutiques \u00e0 long terme et les r\u00e9sultats du traitement au quotidien. <\/strong><\/p>\n\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

Un large \u00e9ventail d’agents syst\u00e9miques est d\u00e9sormais disponible pour le traitement du psoriasis mod\u00e9r\u00e9 \u00e0 s\u00e9v\u00e8re. Lors du congr\u00e8s de la DDG de cette ann\u00e9e “Dermatologie compacte + pratique”, diff\u00e9rentes……... <\/p>\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":555272,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Psoriasis : traitement par des produits biologiques et TYK-2-i","footnotes":""},"category":[11549,11362,11527,11464,11535,11505],"tags":[27094,66106,81441,91663,12625,12408,14035,91665,26407,91664],"powerkit_post_featured":[],"class_list":["post-555271","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-fr","category-dermatologie-et-venerologie","category-etudes","category-pharmacologie-et-toxicologie","category-rapports-de-congres","category-rhumatologie","tag-bimekizumab-fr","tag-deucravacitinib-fr","tag-effets-therapeutiques","tag-inhibiteur-de-la-tyrosine-kinase-2-tyk2","tag-ixekizumab-fr","tag-medicaments-biologiques","tag-psoriasis-fr-2","tag-resultats-du-traitement","tag-risankizumab-fr","tag-tyk-2-i","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-07-02 10:20:45","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":555268,"slug":"valutazioni-dei-progressi-basate-su-dati-attuali-a-lungo-termine-e-reali","post_title":"Valutazioni dei progressi basate su dati attuali a lungo termine e reali.","href":"https:\/\/medizinonline.com\/it\/valutazioni-dei-progressi-basate-su-dati-attuali-a-lungo-termine-e-reali\/"},"pt_PT":{"locale":"pt_PT","id":555265,"slug":"avaliacoes-de-progresso-baseadas-em-dados-actuais-de-longo-prazo-e-em-dados-do-mundo-real","post_title":"Avalia\u00e7\u00f5es de progresso baseadas em dados actuais de longo prazo e em dados do mundo real","href":"https:\/\/medizinonline.com\/pt-pt\/avaliacoes-de-progresso-baseadas-em-dados-actuais-de-longo-prazo-e-em-dados-do-mundo-real\/"},"es_ES":{"locale":"es_ES","id":555262,"slug":"evaluaciones-de-progreso-basadas-en-datos-actuales-a-largo-plazo-y-del-mundo-real","post_title":"Evaluaciones de progreso basadas en datos actuales a largo plazo y del mundo real","href":"https:\/\/medizinonline.com\/es\/evaluaciones-de-progreso-basadas-en-datos-actuales-a-largo-plazo-y-del-mundo-real\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/555271","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=555271"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/555271\/revisions"}],"predecessor-version":[{"id":555273,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/555271\/revisions\/555273"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/555272"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=555271"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=555271"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=555271"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=555271"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}